[Evaluation of blood rheology indices in patients with pheochromocytoma].
Investigated group consisted of 28 patients (21 female and 7 male) with pheochromocytoma in mean age of 39.9 +/- 13 years, while control group comprised 25 healthy volunteers in mean age 36.0 +/- 7.2 years. Following parameters were determined: plasma and blood viscosity, erythrocyte and platelets aggregation, erythrocyte deformability, hematocrit, beta-thromboglobulin plasma concentration, plasma fibrinogen concentration, lipids concentration, noradrenaline, adrenaline, serotonin, neuropeptide Y plasma concentrations. Plasma fibrinogen and beta-thromboglobulin were increased in pheochromocytoma before surgery after pharmacological treatment and also after excision of the tumor. Whereas altered erythrocyte deformability before any treatment, only. Plasma neuropeptide Y concentration was higher in pheochromocytoma before surgery and after pharmacological treatment. There was no correlation between plasma catecholamines, plasma fibrinogen, beta-thromboglobulin, and erythrocyte deformability. Our results suggest that rheological abnormalities observed in patients with pheochromocytoma may contribute to vascular complications in this subjects. Sympathetic nervous system seems to influence indirectly observed rheological abnormalities.
Berent
H
H
Kliniki Nadciśnienia Tetniczego i Chorób Naczyń Akademii Medycznej w Warszawie.
Wocial
B
B
Kuczyńska
K
K
Kochmański
M
M
Ignatowska-Switalska
H
H
Januszewicz
A
A
Lapiński
M
M
Lewandowski
J
J
Januszewicz
W
W
D000328:Adult; D004907:Erythrocyte Deformability; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009478:Neuropeptide Y / Q000097:blood; D010673:Pheochromocytoma / Q000503:physiopathology* / Q000628:therapy; D012212:Rheology; D013564:Sympathetic Nervous System / Q000503:physiopathology; D001620:beta-Thromboglobulin / Q000378:metabolism
D009478:Neuropeptide Y; D001620:beta-Thromboglobulin; D005340:Fibrinogen
Ocena wskaźników reologicznych krwi u chorych z pheochromocytoma.